ArticleSpinal cord2026
Temporal trends in gabapentinoid use for the acute management of spinal cord injury: a retrospective cohort study.
Article in Spinal cord, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
STUDY
designRetrospective cohort study.
objectivesThe primary objective was to examine changes in gabapentinoid prescribing among individuals with acute spinal cord injury. The secondary objective was to examine the effects of gabapentinoid prescriptions on neurological recovery.
settingIntensive Care Unit, Vancouver General Hospital, British Columbia, Canada.
methodsIndividuals admitted between 2010 and 2019 with cervical spinal cord injuries were identified from the Rick Hansen Spinal Cord Injury Registry (RHSCIR). The primary outcome was first gabapentinoid prescription following injury, and exposure was year of injury. The secondary outcome was recovery in sensorimotor function, measured by changes in American Spinal Injury Association (ASIA) Impairment Scale (AIS) grades between admission and discharge. We analyzed associations between gabapentinoid prescriptions and year of injury using Cox regression, and neurological recovery using multivariable logistic regression.
resultsOf 257 individuals with cervical spinal cord injury, 79% (n = 204) were prescribed a gabapentinoid within 30 days of injury. Rates of gabapentinoid prescription in the 30 days following injury increased from 41% in 2010/2011 to 93% in 2018/2019. In a subgroup analysis of individuals with incomplete injuries, early (i.e., hyperacute; <5 days post-injury) gabapentinoid use was significantly associated with greater neurological recovery (adjusted OR = 2.9, 95% CI, 1.1 to 7.9).
conclusionsGabapentinoid prescribing in acute spinal cord injury shifted markedly between 2010 and 2019, and was associated with improved neurological recovery in individuals with incomplete injuries. Further study is warranted to assess prescribing practices at other acute care hospitals and to characterize long-term safety.
Indexed as
Identifiers
41644828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.